Novartis has eyes for Alcon

Share this article:
Novartis shelled out $10.4 billion to Nestle for a 25% stake in eye care company Alcon.

The drugmaker holds exclusive rights to acquire Nestle's remaining 52% share in the company under an option commencing January 1, 2010, and running through July 31, 2011.

The acquisition would broaden Novartis' consumer ophthalmic franchise, a useful hedge at a difficult time for pharma. Fort Worth, TX-based Alcon's products include: the Opti-Free contact lens care franchise, along with Systane lubricant drops and I-Caps eye vitamin drops; surgical products including AcrySof lenses; eye allergy drop Patanol and ear infection treatment Ciprodex. Novartis ophthalmic products include its CIBA Vision contact lens line and, outside of the US, wet AMD treatment Lucentis.
 
As part of the deal, Novartis chairman and CEO Daniel Vasella joins Alcon's board of directors, along with Nestle EVP/CFO James Singh.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...